Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of $0.42, $0.28 better than the analyst estimate of $0.14. Revenue for the quarter came in at $278.6 million versus the consensus estimate of $277.08 million.

GUIDANCE:

Acadia Pharma sees FY2025 revenue of $1.07-1.095 billion, versus the consensus of $1.071 billion.
NUPLAZID net product sales in the range of $685 to $695 million, compared with the prior guidance range of $665 to $690 million.
DAYBUE net product sales in the range of $385 to $400 million, compared with the prior guidance range of $380 to $405 million*.
R&D expense in the range of $335 to $345 million, compared with the prior guidance range of $330 to $350 million.
SG&A expense in the range of $540 to $555 million, compared with the prior guidance range of $535 to $565 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.